Imatinib | Search results | NICE

Showing 16 to 23 of 23 results for imatinib

Sort by

Past appeals and decisions
Past technology appraisal appeals and decisions
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]
Discontinued Reference number: GID-TAG360
Result type
Technology appraisal guidance
Status
Discontinued
Midostaurin for treating advanced systemic mastocytosis (TA728)
Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.
Result type
Technology appraisal guidance
Published
22 September 2021
View recommendations for TA728
Show all sections
Sections for TA728
Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]
Discontinued Reference number: GID-TAG408
Result type
Technology appraisal guidance
Status
Discontinued
Avapritinib for treating advanced systemic mastocytosis (TA1012)
Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.
Result type
Technology appraisal guidance
Published
6 November 2024
View recommendations for TA1012
Show all sections
Sections for TA1012
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA196)
This guidance has been replaced by NICE technology appraisal guidance 326.
Result type
Withdrawn guidance
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241)
This guidance has been updated and replaced by NICE technology appraisal guidance 425.
Result type
Withdrawn guidance
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (TA251)
This guidance has been updated and replaced by NICE technology appraisal guidance 426.
Result type
Withdrawn guidance